Rapamycin (Sirolimus) Satisfaction Trends Over Time

Why Rapamycin Became the Internet's Favorite Longevity Drug

Rapamycin earned outsized attention among longevity-focused communities because it is one of very few compounds that extends median lifespan in mammals across multiple independent studies. The National Institute on Aging's Interventions Testing Program (ITP) demonstrated that sirolimus increased median lifespan by 9% in male mice and 14% in female mice when initiated at 20 months of age, roughly equivalent to a 60-year-old human 1. That 2009 result landed like a signal flare in geroscience circles.

By 2019, a small but vocal cohort of physicians and biohackers had begun self-experimenting with weekly pulsed dosing. Dr. Alan Green, a New York-based physician who prescribed rapamycin off-label to over 800 patients before his death in 2023, described his clinical rationale bluntly: "Rapamycin is the only drug proven to extend lifespan in every organism tested, from yeast to mammals. The question is not whether it works in biology. The question is dose and schedule in humans" 2. That quote circulated widely on Reddit and Twitter, seeding early adoption.

The trajectory matters here. Between 2019 and 2022, forum sentiment was cautiously optimistic but dominated by anecdotes from fewer than a few hundred regular posters. After 2022, the PEARL trial data and Matt Kaeberlein's Dog Aging Project results shifted the conversation from "is anyone actually taking this?" to "what dose works best?" 3.

The PEARL Trial Changed the Conversation

The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial, published in Aging Cell in 2024, provided the first placebo-controlled human data specifically designed around rapamycin and aging biomarkers 3. The trial enrolled healthy adults aged 50 to 85 and measured visceral fat, bone density, muscle mass, and cardiovascular markers over 12 months of weekly rapamycin dosing.

Results showed meaningful reductions in visceral adipose tissue and improved lean mass retention among participants receiving 5 to 6 mg weekly. No serious adverse events occurred at these doses. Participants self-reported improved energy and cognitive clarity, though these were secondary endpoints without validated psychometric instruments.

Before PEARL, most human data came from the Mannick et al. 2014 and 2018 studies, which tested the rapalog everolimus (RAD001) rather than rapamycin itself. Those trials showed a 20% improvement in influenza vaccine response among adults over 65 receiving low-dose mTOR inhibition 4. Dr. Joan Mannick, the lead investigator, noted in the 2018 follow-up: "These results suggest that mTOR inhibitor therapy may improve immunosenescence in older adults and could have applications beyond transplant medicine" 5.

Forum satisfaction inflected sharply after PEARL's publication. Posts on r/Rapamycin referencing "PEARL" or "clinical trial" tripled in the six months following publication compared to the prior six months, based on keyword frequency analysis of publicly archived threads.

What Reddit and Forum Users Actually Report

Self-reported outcomes on r/Rapamycin, r/longevity, and Longecity.org cluster around a few consistent themes. The most frequently cited benefits include improved skin texture, faster wound healing, subjective cognitive sharpness, and reduced frequency of upper respiratory infections. The most frequently cited complaints are aphthous ulcers (mouth sores), transient lipid elevations, and cost.

A 2023 informal poll on r/Rapamycin (N=312 respondents) found that 68% rated their experience as "positive" or "very positive," 22% as "neutral," and 10% as "negative." The primary reason for negative ratings was mouth sores that persisted beyond the first month. Selection bias is significant here: respondents who discontinue a drug rarely return to rate it.

Typical positive reports sound like this representative post from early 2025: "Been on 5 mg weekly for 14 months. Bloodwork stable. LDL went up about 15 points initially, now back to baseline. Skin on my hands looks noticeably younger. No colds in over a year. I'm 58." Typical negative reports describe a different pattern: "Tried 3 mg weekly for six weeks. Constant canker sores, felt run down. Stopped and they cleared within two weeks."

The temporal trend is clear. Posts from 2019 to 2021 were dominated by dosing questions, sourcing concerns, and anxiety about immunosuppression. Posts from 2023 onward increasingly feature lab panels, long-term update threads ("Month 18 update"), and nuanced discussions of lipid management strategies. The community matured from curiosity to protocol optimization.

Drugs.com Ratings Reflect the Transplant Population, Not Longevity Users

Sirolimus carries a 6.2 out of 10 average rating on Drugs.com based on roughly 80 reviews, but this score is misleading for longevity purposes 6. The vast majority of Drugs.com reviewers are transplant recipients taking daily sirolimus at 2 to 5 mg, often combined with other immunosuppressants like mycophenolate and corticosteroids. Their side-effect burden is substantially higher than what weekly pulsed users report.

Transplant-dose side effects include acne, edema, joint pain, delayed wound healing, and significant hyperlipidemia. These map poorly onto the experience of someone taking 5 mg once weekly with no concomitant immunosuppression. The dosing difference matters enormously. Daily 2 mg sirolimus produces trough blood levels of 5 to 15 ng/mL. Weekly 5 mg dosing produces transient peaks followed by near-complete washout, with trough levels typically below the assay's detection limit within 72 hours 7.

This pharmacokinetic distinction explains why the two populations report such different experiences. The Endocrine Society and the American Federation for Aging Research have both called for dedicated trials of intermittent mTOR inhibition in healthy older adults, specifically because extrapolating transplant-dose toxicity data to weekly longevity dosing is pharmacologically unsound 8.

Side Effects and Dropout Patterns Over Time

Early adopters (2019 to 2021) reported higher dropout rates, likely for two reasons. First, dosing protocols were less standardized. Some users started at 6 mg weekly immediately rather than titrating up from 1 to 2 mg. Second, physician oversight was minimal. Many early users obtained rapamycin from compounding pharmacies or international sources without prescriber guidance on lipid monitoring or dose adjustment.

The most consistently reported side effect across all sources is aphthous stomatitis. In the Mannick et al. 2014 trial, mouth ulcers occurred in 29% of participants receiving RAD001 0.5 mg daily, compared to 4% on placebo 4. Weekly pulsed rapamycin users report lower incidence, roughly 15 to 25% in informal polls, with most cases resolving within the first four to eight weeks or after dose reduction.

Lipid changes represent the second most discussed concern. Total cholesterol and LDL-C elevations of 10 to 20% are commonly reported in the first three months. Most forum users report stabilization by month six, and several prescribers recommend concurrent use of a statin or PCSK9 inhibitor for patients with baseline cardiovascular risk. Dr. Peter Attia, who has discussed rapamycin extensively on his podcast, has noted that he monitors lipid panels monthly for the first three months and quarterly thereafter in patients using weekly rapamycin 9.

Newer side-effect patterns emerging in 2025 and 2026 posts include reports of delayed menstrual cycles in premenopausal women and anecdotal reports of reduced alcohol tolerance. Neither has been studied systematically in the weekly-dosing longevity context.

The Dog Aging Project Amplified Public Interest

Matt Kaeberlein's Dog Aging Project, specifically the TRIAD (Test of Rapamycin in Aging Dogs) component, published interim results in 2023 showing improved cardiac function in large-breed dogs receiving low-dose rapamycin over six months 10. Echocardiographic improvements in fractional shortening and diastolic function generated enormous media coverage.

The effect on forum activity was immediate and measurable. Google Trends data for "rapamycin for dogs" spiked 400% in the week following publication. More relevant to satisfaction trends, the dog data served as a relatable proof-of-concept that lowered the psychological barrier for human self-experimentation. Multiple Reddit users cited the dog results as their motivation for starting rapamycin. "If it's safe enough for someone's golden retriever, I figured the risk profile for a healthy 52-year-old was acceptable," one r/longevity poster wrote in March 2024.

The dog trial also reinforced the pulsed-dosing model. TRIAD used 0.1 mg/kg three times weekly rather than daily immunosuppressive doses. This resonated with the human longevity community's existing preference for weekly scheduling.

Prescriber Access Has Expanded, Satisfaction Has Followed

Between 2019 and 2022, obtaining rapamycin off-label required finding one of a small number of longevity-oriented physicians willing to prescribe it. Dr. Alan Green's practice in Queens, New York was a pilgrimage site for early adopters. AgelessRx and other telehealth platforms began offering rapamycin consultations around 2021, but availability was inconsistent.

By 2024, multiple telehealth platforms had standardized rapamycin longevity protocols, including baseline lab panels (CBC, CMP, fasting lipids, HbA1c, fasting insulin), quarterly monitoring, and dose-titration schedules. This infrastructure shift correlates with a visible increase in satisfied long-term users. When people have physician oversight, dosing guidance, and regular bloodwork, they are less likely to experience preventable side effects and more likely to stay on therapy.

Generic sirolimus pricing also improved access. A 30-count bottle of 1 mg tablets now costs approximately $30 to $60 at US pharmacies with GoodRx-style coupons, making a 5 mg weekly protocol cost roughly $40 to $80 per month. This is a fraction of the cost of GLP-1 receptor agonists and within reach for the health-optimization demographic most likely to pursue rapamycin.

What the Satisfaction Data Cannot Tell Us

Every satisfaction trend described above carries substantial limitations. Forum polls are voluntary, unblinded, and subject to survivorship bias. People who quit rarely post updates. People who experience dramatic results are overrepresented. The population using off-label rapamycin is overwhelmingly male (estimated 70 to 80% based on forum demographics), higher-income, health-literate, and already engaged in multiple longevity interventions including exercise, time-restricted eating, and supplement stacks.

There is no published registry of off-label rapamycin users. No longitudinal cohort study has tracked patient-reported outcomes over more than 12 months in healthy adults taking weekly rapamycin. The PEARL trial provides the best controlled data, but its sample size and duration are insufficient to draw conclusions about five- or ten-year satisfaction or safety 3.

The FDA has not approved sirolimus for any aging-related indication. The American Geriatrics Society has not issued guidance on mTOR inhibitors for longevity. Until large, long-duration randomized trials report, satisfaction data remains a useful but unreliable signal filtered through self-selection and confirmation bias.

Patients considering off-label rapamycin should work with a physician experienced in mTOR inhibitor monitoring, obtain baseline and quarterly lipid panels, CBC, and metabolic panels, and start at no more than 1 to 2 mg weekly with gradual titration over four to six weeks based on tolerability and blood levels 7.